Ting KKY, Yu P, Dow R, Ibrahim H, Karim S, Polenz CK, et al
Biochimica et Biophysica Acta (BBA)-Biomembranes
Beyond weight loss and glucose control, how do you see GLP-1 agonists being leveraged to treat other conditions, such as cardiovascular disease, chronic kidney disease, sleep apnea, or osteoarthritis
These markers reveal whether menopause weight gain stems primarily from insulin dysregulation, appetite signaling dysfunction, or other metabolic driverseach suggesting different GLP-1 formulation strengths and dosing strategies
Heres whats really going on
Similar to semaglutide and long-acting GIP, treat- ment with LY improved glucose excursions in all 3 genotypes (Figures 1G1I)